Ixekizumab reduces disease activity up to 52 weeks in active psoriatic arthritis patients with inadequate response to tumor necrosis factor inhibitors: An assessment with the use of minimal disease activity scores

Merola, JF, Coates, LC, Husni, ME et al. (3 more authors) (2018) Ixekizumab reduces disease activity up to 52 weeks in active psoriatic arthritis patients with inadequate response to tumor necrosis factor inhibitors: An assessment with the use of minimal disease activity scores. In: Journal of the American Academy of Dermatology. American Academy of Dermatology 2018 Annual Meeting, 16-20 Feb 2018, San Diego, California, USA. Elsevier , AB174-AB174.